Screener Summaries Updates Institutions Sign In More Updates › Other Events › ALKS Other Events · Jun 15, 2026
On June 15, 2026, Alkermes plc announced that the U.S. Food and Drug Administration granted orphan drug designation to… ALKS Alkermes plc.
On June 15, 2026, Alkermes plc announced that the U.S. Food and Drug Administration granted orphan drug designation to alixorexton for treating idiopathic hypersomnia. Additionally, the European Commission granted orphan drug designation to alixorexton for the treatment of narcolepsy. Alkermes plc is a biopharmaceutical company focused on developing medical treatments.
More from Alkermes plc. Alkermes reports Q3 revenues of $480.1M and GAAP net income of $16.3M Nov 3, 2026 Alkermes reports positive phase 1 results for ALKS 7290 in ADHD, showing dose-dependent symptom reductions Sep 21, 2026 Alkermes appoints Anne C. Whitaker to board with $600,000 new director award Sep 16, 2026 Alkermes plc entered into Amendment No. 1 to its Credit Agreement on August 12, 2026, reducing the interest rate… Aug 12, 2026 Alkermes plc appointed Blair C. Jackson as President and Chief Executive Officer, effective August 1, 2026 Aug 3, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
